New compound protects against mustard gas

Aeolus Pharmaceuticals, Inc., announced that in a second study, its lead compound, Aeol 10150, protected rats from lung damage caused by mustard gas. 

Researchers from the National Jewish Health and Lovelace Respiratory Research Institute were tasked with determining whether or not Aeol 10150, if administered every six hours after initial exposure, was capable of reducing acute lung injury from sulfur mustard vapor.

Business Wire reported that the results of the test, evaluated through the consistency of vapor-induced pulmonary edema, demonstrated complete protection.

“This study confirms AEOL 10150’s potential as an effective countermeasure for mustard gas exposure," John McManus, president and CEO of Aeolus Pharmaceuticals, Inc., said. "The compound has now shown statistically significant efficacy in two whole mustard studies and several studies using CEES (or half mustard).”

McManus added that a new study has already begun to examine AEOL 10150’s ability to protect from exposure to higher concentrations of mustard gas. The research is part of a five year, $7.8 million grant awarded to National Jewish Health by the National Institute of Health to find a treatment.

Mustard gas, first used as a weapon in World War I, is still considered a potential threat. Skin blistering, respiratory damage and fibrosis are the most common effects of exposure.

Organizations in this Story

Aeolus Pharmaceuticals

Want to get notified whenever we write about Aeolus Pharmaceuticals ?
Next time we write about Aeolus Pharmaceuticals, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.